{
  "trial_id": "NCT01296503",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "symptomatic multiple myeloma in accordance with the International Myeloma Working Group criteria",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "age 18-70 years",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Performance status 0-2 by the Eastern Cooperative Oncology Group (ECOG) criteria",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "normal hepatic function, defined as serum bilirubin <3 mg/dl and alanine aminotransferase(ALT) and asparagin aminotransferase (AST) <4x normal",
      "label": "met",
      "evidence": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "evidence of disease progression after ASCT",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "cardiac dysfunction (systolic ejection fraction <50%)",
      "label": "triggers",
      "evidence": "none"
    }
  ],
  "notes": "Patient has multiple myeloma with systemic amyloidosis and is on hemodialysis for ESRD. She was admitted last week with hypercalcemia and treated with pamidronate, calcitonin, and dialysis.",
  "_meta": {
    "topic_id": "17",
    "trial_id": "NCT01296503",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}